New bowel cancer test shows greater than 90% accuracy in high-risk patients
Experts hope to create a blood test to see which patients with inflammatory bowel disease are most at risk of bowel cancer.
Teva's Growth Profile Looks Strong From Innovative Portfolio, Biosimilar Approvals and Deep Pipeline
We assign Teva a Morningstar Uncertainty Rating of High, which largely reflects our quantitative analysis of the firm, based on the return ranges used by our star rating system, as well as our ...
Teva Pharmaceutical Industries (TEVA) Q4 2024 Earnings Call Transcript
Operator Hello, and welcome to the fourth quarter and full year 2024 Teva Pharmaceutical Industries earnings conference call.
Bone broth is going viral for anti-aging and weight loss benefits. Does it work? Experts explain
Bone broth is high in protein and nutrients. What are the health benefits and is it okay to have bone broth every day?
Ibj.com21h
Lilly’s Omvoh part of company’s expansion into inflammatory bowel disease treatment
The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...
gastroenterologyadvisor20h
Severe Histologic Disease Activity in UC Raises Risk of Biologic-Associated Colectomy
Baseline histologic activity predicted colectomy risk in ulcerative colitis treated with biologics, independent of clinical or endoscopic factors.
gastroenterologyadvisor20h
FDA Approves New Vial Sizes for GVHD Treatment Niktimvo
The FDA has approved 2 additional vial sizes of Niktimvo™ (axatilimab-csfr), 9mg/0.18mL and 22mg/0.44mL, in addition to the 50mg/mL size.